CytomX Therapeutics (CTMX) Scheduled to Post Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is scheduled to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect CytomX Therapeutics to post earnings of ($0.16) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $25.12 million during the quarter, compared to analysts’ expectations of $21.79 million. CytomX Therapeutics had a negative return on equity of 27.44% and a net margin of 9.27%. During the same period in the prior year, the company posted ($0.02) earnings per share. On average, analysts expect CytomX Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CytomX Therapeutics Price Performance

CytomX Therapeutics stock traded down $0.01 during mid-day trading on Tuesday, hitting $1.00. The company’s stock had a trading volume of 563,313 shares, compared to its average volume of 2,572,858. CytomX Therapeutics has a 52-week low of $0.99 and a 52-week high of $5.85. The firm’s 50 day moving average is $1.15 and its 200 day moving average is $1.49. The company has a market cap of $78.12 million, a PE ratio of 7.14 and a beta of 1.06.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, September 13th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.